Trial · NCT07598474
Pregabalin Phonophoresis and MET for Knee Osteoarthritis
NCT07598474, Not applicable, Recruiting, University of Faisalabad
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Pregabalin Phonophoresis and MET for Knee Osteoarthritis. Trials, record NCT07598474. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07598474
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Pregabalin Phonophoresis and MET for Knee Osteoarthritis
- NCT number
- NCT07598474
- Status
- Recruiting
- Phases
- Not applicable
- Enrollment
- 35 participants, estimated
- Lead sponsor
- University of Faisalabad
- Conditions
- Knee Osteoarthritis
- Interventions
- Pregabalin-Encapsulated Hydrogel Phonophoresis, Gastrocnemius Muscle Energy Technique (Post-Isometric Relaxation), Aqua Gel Phonophoresis
- First posted
- 2026-05-20
- Last updated
- 2026-05-20
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Neuropathic Pain Component | Baseline (week 0, pre-intervention) and Week 4 (post-intervention, after 16 sessions) | Douleur Neuropathique 4 (DN-4) questionnaire. A validated 4-question (7-item) screening tool for neuropathic pain. Questions 1-2: patient interview regarding pain characteristics (burning, painful cold, electric shocks, tingling, pins and needles, numbness, itching). Questions 3-4: physical examination (hypoesthesia to touch, hypoesthesia to pinprick, brushing-evoked pain). Each item scored 0 (no) or 1 (yes). Total score range 0-10. A score ≥4 indicates presence of neuropathic pain component. Higher scores indicate greater neuropathic pain. Minimal clinically important difference for DN-4 in osteoarthritis: 2 points. |
| Secondary | Change in Pain Intensity | Baseline (week 0, pre-intervention) and Week 4 (post-intervention, after 16 sessions) | Numeric Pain Rating Scale (NPRS). An 11-point scale from 0 to 10 where 0 = "no pain" and 10 = "worst pain imaginable." Participants rate their average knee pain over the past 24 hours. Administered verbally by outcome assessor. Minimal clinically important difference for knee osteoarthritis: 2 points. |
| Secondary | Change in Functional Mobility and Stiffness | Baseline (week 0, pre-intervention) and Week 4 (post-intervention, after 16 sessions) | Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). A standardized, validated, disease-specific questionnaire for hip and knee osteoarthritis. Three subscales: Pain (5 items, score 0-20), Stiffness (2 items, score 0-8), Physical Function (17 items, score 0-68). Total score range 0-96. Higher scores indicate worse pain, stiffness, and functional limitation. Administered by self-report (paper form) with assistance if needed. Minimal clinically important difference for total WOMAC in knee osteoarthritis: 12-15 points. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07598474
GET https://conductscience.org/api/trials/v1/NCT07598474/registered